Cardiff Oncology Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
CRDF$0.73-4.9%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
Checking your notes…
| Preferred Stock Shares · Preferred Stock Amount · Common Stock Shares · Common Stock Amount · Additional Paid-In Capital · Service Receivable · Accumulated other comprehensive loss · Accumulated Deficit · TotalStockholders’ Equity | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2021 | 716 | $1 | 41,964 | $4 | $400,503 | $(139) | $(142) | $(259,810) | $140,417 | ||||||
| Stock-based compensation | — | — | — | — | 4,256 | — | — | — | 4,256 | ||||||
| Issuance of common stock upon exercise of stock options | — | — | 29 | — | 75 | — | — | — | 75 | ||||||
| Issuance of common stock upon conversion of Series E Convertible Preferred Stock | (655) | (1) | 2,684 | — | — | — | — | — | (1) | ||||||
| Other comprehensive loss | — | — | — | — | — | (253) | — | (253) | |||||||
| Release of clinical trial funding commitment | — | — | — | — | 139 | — | — | 139 | |||||||
| Cumulative preferred stock dividend adjustment | — | — | — | — | — | — | — | 414 | 414 | ||||||
| Net loss | — | — | — | — | — | — | (38,704) | (38,704) | |||||||
| Balance, December 31, 2022 | 61 | — | 44,677 | 4 | 404,834 | — | (395) | (298,100) | 106,343 | ||||||
| Stock-based compensation | — | — | — | — | 4,509 | — | — | — | $4,509 | ||||||
| Other comprehensive gain | — | — | — | — | — | — | 328 | — | $328 | ||||||
| Net loss | — | — | — | — | — | — | — | (41,441) | $(41,441) | ||||||
| Balance, December 31, 2023 | 61 | $— | 44,677 | $4 | $409,343 | $— | $(67) | $(339,541) | $69,739 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.